Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year' [Yahoo! Finance]
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... [Yahoo! Finance]
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update